NCT05378607Active, not recruiting
Goals for Adherence With Low-cost Incentives
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
GOALS is a three-year randomized control trial (RCT) aimed at testing the effectiveness of three incentive designs to improve the ART adherence of those in need of adherence support. Participants in the first treatment group (T1, n=140) will be eligible for a prize drawing every three months if they reach the adherence target set for them by the study team, gradually increasing from their baseline adherence towards 90% by the end of the year. Participants in the second treatment group (T2, n=140) will be eligible if they reach the adherence target they set for themselves (subject to reaching 90% at the end of year 1 and each target being at least as high as the previous one). Participants in the third treatment group will have a fixed adherence target of 90% and will be eligible for a prize drawing every three months if this target is reached. All treatment groups will receive weekly motivational messages and a reminder of the upcoming prize drawing. The control group (T4, n=140) will receive the usual standard of care offered by the hospital and weekly motivational messages. Primary outcomes measured using Wisepill devices are mean ART adherence and the fraction of clients with adherence of 90% or more. Secondary outcomes are viral suppression, the fraction of clients with treatment interruptions of 48hrs or more, and retention in care.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 560 (estimated)
- First submitted
- 8 May 2022
- Start date
- 18 Apr 2022
- Primary completion date
- 11 Feb 2027
- Lead sponsor
- RAND
- Diseases
- HIV
- NCT number
- NCT05378607
What you commit to
- Study type: Interventional
- Planned participants: 560
- From 18 Apr 2022 to the primary completion date, 11 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- has not received ART from Mildmay for at least three months,
- cannot use a Wisepill device when taking ART medication,
Age
- If the participant is not within the age range specified above,
Other
- cannot follow the consenting procedures
- does not have regular access to a mobile phone (at least five days per week)
- or shows Wisepill-measured adherence of over 90%
Who the study is looking for
- If the participant is between 15 and 30 years of age (inclusive),
- has received ART from Mildmay for at least three months,
- exhibits Wisepill-measured adherence of under 90%,
- and has regular access to a mobile phone (at least five days per week)
Age in the registry: 15 years to 30 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mildmay Uganda Coordinator of this site? Confirm its status | Kampala | Uganda | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.